New hope for Behcet's patients: drug TA-650 targets tough lesions

NCT ID NCT01532570

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug TA-650 (infliximab) in 18 people with Behcet's disease who had hard-to-treat lesions. The drug was given by IV every few weeks for nearly a year. The goal was to see if symptoms and signs of inflammation could be completely controlled. The trial is complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TA-650 (infliximab, a biologic drug that blocks inflammation)
What this could lead to: If it works, this could point toward a treatment option for people with Behcet's disease who have severe lesions not helped by standard therapies.
What could go wrong: This is a small, completed Phase 3 trial with only 18 participants, so results may not apply to everyone. The drug is already approved for other conditions, but its benefits for Behcet's special lesions remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHCET SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behcet disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BEHCET SYNDROME BEHCET'S DISEASE NEURO-BEHCET'S DISEASE

Contacts and locations

Locations

Investigational site

Chūbu, Japan
Investigational site

Hokkaido, Japan
Investigational site

Kanto, Japan
Investigational site

Kinki, Japan
Investigational site

Kyusyu, Japan
Investigational site

Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.